Biolojic Design, a biotech company specializing in AI-driven antibody innovation, announced that Nektar has exercised its license option to develop a program resulting from their collaborative research started in 2021. This joint effort focused on designing and testing agonistic antibodies targeting tumor necrosis factor receptor type II (TNFR2), a challenging-to-address biological target implicated in various autoimmune diseases.The selected antibody program, now referred to as NKTR-0165, aims to modulate the TNFR2 pathway to activate T regulatory cells and other anti-inflammatory cell populations.

Biolojic Design是一家专门从事人工智能驱动的抗体创新的生物技术公司，它宣布Nektar已行使其许可选择权，开发一个由他们于2021年开始的合作研究产生的项目。这项联合努力的重点是设计和测试靶向肿瘤坏死因子受体II型（TNFR2）的激动性抗体，这是解决与各种自身免疫性疾病有关的生物靶标的挑战。选择的抗体程序，现在称为NKTR-0165，旨在调节TNFR2途径以激活T调节细胞和其他抗炎细胞群。

This novel approach holds promise for enhancing the immune system in conditions such as ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune diseases. Nektar, in accordance with the 2021 research agreement, has evaluated antibodies computationally designed by Biolojic Design to precisely target the TNFR2 receptor.Following successful preclinical tests in vitro and in vivo, Nektar has chosen to advance the program through studies aimed at preparing for Investigational New Drug (IND) application since late December 2023.

这种新方法有望在溃疡性结肠炎，多发性硬化症，白癜风和其他自身免疫性疾病等疾病中增强免疫系统。根据2021年研究协议，Nektar评估了通过Biolojic设计计算设计的抗体，以精确靶向TNFR2受体。自2023年12月下旬以来，Nektar在成功进行体外和体内临床前试验后，选择通过旨在准备研究性新药（IND）应用的研究来推进该计划。

If the NKTR-0165 candidate progresses through clinical development, Biolojic Design is entitled to receive development milestones and royalties from sales.Yanay Ofran, Ph.D., CEO and founder of Biolojic Design, stated, 'The unique agonist antibodies targeting TNFR2 highlight the effectiveness of Biolojic’s AI platform for antibody design.

如果NKTR-0165候选人通过临床开发取得进展，Biolojic Design有权从销售中获得开发里程碑和版税。Biolojic Design首席执行官兼创始人Yanay Ofran博士表示，“针对TNFR2的独特激动剂抗体突显了Biolojic AI平台在抗体设计中的有效性。

These antibodies can not only functionally activate TNFR2 but also do so in a highly distinctive manner. We eagerly anticipate Nektar’s progress with this promising molecule through clinical development, potentially benefiting numerous autoimmune disease patients.'Jonathan Zalevsky, Chief Research and Develo.

这些抗体不仅可以在功能上激活TNFR2，而且还可以以高度独特的方式激活TNFR2。我们热切期待Nektar通过临床开发在这种有前途的分子方面取得进展，这可能会使许多自身免疫性疾病患者受益。”乔纳森·扎列夫斯基（JonathanZalevsky），首席研发官。